Lisdexamfetamine
- Generic Name
- Lisdexamfetamine
- Brand Names
- Vyvanse
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25N3O
- CAS Number
- 608137-32-2
- Unique Ingredient Identifier
- H645GUL8KJ
- Background
Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.
- Indication
Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults. It is approved for use in the US and Canada.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Moderate Binge Eating Disorder (BED), Severe Binge Eating Disorder (BED)
- Associated Therapies
- -
To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder
- Conditions
- Attention Deficit/Hyperactivity DisorderBipolar Disorder
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 45
- Registration Number
- NCT01263548
- Locations
- 🇨🇦
Mood Disorders Psychopharmacology Unit, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.